Eureka’s manuscript on targeting alpha-fetoprotein (AFP) with a CAR T cell therapy for the treatment of liver cancer is published in Clinical Cancer Research on August 17, 2016.
This paper describes Eureka’s unique approach to redirecting T cells against solid tumors. The company overcomes one of the key challenges in targeting solid tumors with T cell immunotherapies, which is the lack of tumor-specific antigens that are membrane-expressed. Eureka successfully introduced its novel approach against solid tumors by developing a fully human antibody against a peptide-MHC complex derived from the intracellularly-expressed and secreted liver cancer-specific marker AFP. This antibody, when engineered into a second generation CD28z CAR, specifically and potently kills liver cancer cells in vitro and in vivo.
“Our work demonstrate a novel approach against solid tumors.” said Cheng Liu,the President and CEO of Eureka Therapeutics. “And most importantly, provides a potential new therapy for a disease with extremely limited treatment options.”
To read the paper: http://clincancerres.aacrjournals.org/content/early/2016/08/17/1078-0432.CCR-16-1203
